Calidi Biotherapeutics Inc. (NYSE American: CLDI) Data Demonstrates Potential of Innovative Solutions to Revolutionize Cancer Care

• Emerging therapies, advanced diagnostic tools and groundbreaking research are reshaping the fight against cancer.
• Calidi Biotherapeutics uses stem cells and cell-enveloping technologies to deliver virotherapy payloads that attack cancers and leave healthy cells untouched.
• RTNova is designed to address the limitations of traditional virotherapy by offering enhanced targeting, systemic delivery and immune system modulation.

Cancer continues to be a leading cause of morbidity and mortality worldwide, affecting millions of lives every year. While advances in prevention, early detection and treatment have made strides in reducing the global cancer burden, innovation remains critical to achieving further breakthroughs. Emerging therapies, advanced diagnostic tools and groundbreaking research are reshaping the fight against cancer, offering new hope for patients and their families.

A compelling example of this progress is the work of Calidi Biotherapeutics (NYSE American: CLDI), whose recent data on its RTNova(TM) systemic enveloped virotherapy technology demonstrates the potential of cutting-edge solutions to revolutionize cancer care (https://ibn.fm/X06dh).

Cancer is not a single disease but a group of related diseases characterized by abnormal cell growth. This complexity requires diverse and innovative approaches to treatment. Traditional methods such as surgery, chemotherapy and radiation therapy have significantly improved survival rates, but they are not without limitations, including toxicity and resistance. Innovation is vital to overcoming these challenges.

New approaches to cancer treatment leverage technology, biology and chemistry to create therapies that are more effective, less invasive and increasingly personalized. Some key examples include:

• Immunotherapy: Treatments such as checkpoint inhibitors and CAR T-cell therapy harness the body’s immune system to recognize and attack cancer cells.
• Targeted therapy: Drugs designed to target specific mutations in cancer cells have reduced side effects while improving efficacy.
• Oncolytic virotherapy: In this promising area of innovation, viruses are engineered to infect and destroy cancer cells while sparing healthy tissues.
• Precision medicine: Advances in genomic sequencing allow treatments to be tailored to an individual’s genetic profile, optimizing outcomes and minimizing adverse effects.

Calidi Biotherapeutics is at the forefront of cancer treatment innovation, focusing on novel approaches to oncolytic virotherapy using stem cells and cell-enveloping technologies to deliver targeted and effective virotherapy payloads that attack cancers and leave healthy cells untouched. Calidi’s treatments effectively target a primary tumor and then arm the immune system to kill cancer metastases.

At two major conferences—the International Oncolytic Virotherapy Conference (“IOVC”) and the Society for Immunotherapy of Cancer (“SITC”) Annual Meeting—Calidi presented groundbreaking data supporting the capabilities of its proprietary RTNova systemic enveloped virotherapy platform. RTNova is designed to address the limitations of traditional virotherapy by offering enhanced targeting, systemic delivery and immune system modulation. Calidi’s data demonstrated that RTNova can achieve robust tumor-specific replication and destruction, making it a promising candidate for treating a wide range of cancers. Furthermore, this platform can be used as a standalone therapy or in combination with existing treatments like immunotherapy and checkpoint inhibitors to enhance outcomes.

The battle against cancer is far from over, but the momentum of innovation provides a reason for optimism. Companies such as Calidi Biotherapeutics are paving the way for therapies that push the boundaries of what is possible in medicine. In the coming years, advancements such as RTNova and other cutting-edge therapies will undoubtedly continue to shape the cancer treatment landscape.

Calidi Biotherapeutics is a clinical-stage, immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem-cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical-stage, off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease.

For more information, visit www.CalidiBio.com.

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN